Patent intelligence · US
US 12414942
Compositions, methods, and systems for treating presbyopia
Compositions, methods, and systems for treating presbyopia
Patent details — US 12414942
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 16, 2025
- Expiration
- Sep 11, 2045
- Applicant
- LENZ THERAPEUTICS OPERATIONS, INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/439, A61K31/498, A61K9/0048
Quick answer
US 12414942 (Compositions, methods, and systems for treating presbyopia) is held by LENZ THERAPEUTICS OPERATIONS, INC.. Status: granted. Granted Sep 16, 2025. Expires Sep 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LENZ THERAPEUTICS OPERATIONS, INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/439, A61K31/498, A61K9/0048, A61P, A61P27/10
More from LENZ THERAPEUTICS OPERATIONS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12180206
Aceclidine derivatives, compositions thereof and methods of use thereof
granted -
US 12128036
Compositions and methods for storage stable ophthalmic drugs
granted -
US 11648247
Compositions and methods for the treatment of presbyopia
granted -
US 11344538
Methods for the treatment of myopia
granted -
US 11273150
Compositions and methods for the treatment of presbyopia
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11179328
Compositions and methods for the treatment of presbyopia
granted
Frequently asked questions
What is US patent 12414942?
US 12414942 (Compositions, methods, and systems for treating presbyopia) is held by LENZ THERAPEUTICS OPERATIONS, INC.. Status: granted. Granted Sep 16, 2025. Expires Sep 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12414942?
LENZ THERAPEUTICS OPERATIONS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 12414942 expire?
Our index shows an expiration date of Sep 11, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.